blys antagonistic peptide, plasmid containing ta-fc fusion protein gene and ta-fc fusion protein

A fusion protein and antagonistic peptide technology, applied in the field of biomedicine, can solve problems such as short half-life, low efficiency, and unstable peptides

Inactive Publication Date: 2015-12-02
TIANJIN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, peptides also have the disadvantages of instability, low efficiency and short half-life

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • blys antagonistic peptide, plasmid containing ta-fc fusion protein gene and ta-fc fusion protein
  • blys antagonistic peptide, plasmid containing ta-fc fusion protein gene and ta-fc fusion protein
  • blys antagonistic peptide, plasmid containing ta-fc fusion protein gene and ta-fc fusion protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Structural information on the interaction between BLyS and its receptors and the design of novel antagonistic peptides targeting BLyS

[0042] The interaction mode between BLyS and its receptor TACI was explored by computer-aided molecular docking and dynamic simulation, and the key amino acid residues for mutual recognition between BLyS and its receptor were analyzed by means of computer graphics and distance geometry.

[0043] Using computer-aided molecular design and high-throughput virtual screening technology to de novo design short peptides that can simulate the conformation of key amino acids in receptors, and then theoretically evaluate the role of BLyS and antagonistic peptides by means of de novo construction, molecular docking, and kinetic simulation; use computer graphics Biochemical techniques, distance geometry, and intermolecular hydrogen bonding interactions were used to evaluate potential biological effects of antagonistic peptides. After theoretical sc...

Embodiment 2

[0045] Chemical Synthesis of BLyS Antagonistic Peptide

[0046] According to the results of computer-aided design. We commissioned a biological company to prepare BLyS antagonistic peptide (TA), which has a purity of over 95%.

[0047] SampleId: TA, Sequence: DTSKLASTGYSSDPY (SEQ ID NO.1), MolecularWeight: 1591.66, HPLCAnalysis: PeptidePurity>95%.

Embodiment 3

[0049] ELISA experiment to verify the inhibitory activity of antagonistic peptide TA

[0050] Dilute BLyS protein with coating solution to a final concentration of 10 μg / ml, take 50 μL in a microtiter plate, 4°C, 18h. Wash the microtiter plate 3 times with PBST, 5 min each time. Add 150 μl of 5% skimmed milk powder to each well, and incubate at 37°C for 2 hours. Wash the microtiter plate 3 times with PBST, 5 min each time. Mix a fixed concentration of TACI-Fc protein (final concentration of 10 μg / ml) with different concentration gradients of antagonistic peptide TA (final concentrations of 0, 10, 50 and 100 μg / ml), and each concentration has 3 parallels, each well Add 50 μL, and incubate at 37°C for 1h. The irrelevant peptide NP served as a control. Wash the microtiter plate 3 times with PBST, 5 min each time. Add 50 μL of HRP-labeled goat anti-human antibody diluted 1:5000 times to each well, 37°C, 1h. Wash 3 times with PBST, 5min each time. Add 50 μL TMB chromogenic s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a BLyS (B lymphocyte stimulator) antagonist peptide, a plasmid containing a TA-Fc fusion protein gene and a TA-Fc fusion protein. The BLyS antagonist peptide is shown in the SEQ ID No.1 (in the Specification), and is named as TA; the BLyS antagonist peptide TA can restrain the mutual action between BLyS and TACI (Transmembrane activator and CAML-interactor); the TA-Fc fusion protein can be combined with the BLyS, restrains the mutual action between the BLyS and the TACI, and guarantees the spatial structure and stability of the antagonist peptide TA while not weakening the activity of peptide; the TA-Fc fusion protein can be used as a potential BLyS antagonist to be applied to the research and treatment of autoimmune diseases and lymphoma.

Description

technical field [0001] The invention belongs to the field of biomedicine, in particular to a BLyS antagonistic peptide named TA, a plasmid containing a TA-Fc fusion protein gene and a TA-Fc fusion protein. Background technique [0002] B lymphocyte stimulating factor (Blymphocytestimulator, BLyS), also known as B cell activating factor (BcellactivatingfactorbelongingtotheTNFfamily, BAFF), is a member of the TNF family. It is continuously synthesized and secreted by monocytes and macrophages. BAFF can bind three receptors on the surface of B cells, B cell maturation antigen (Bcellmatureantigen, BCMA), transmembrane activator and CAML conjugate (TransmembraneactivatorandCAML-interactor, TACI) and BAFF receptor 3 (BR3). After the receptor binds to BAFF, it is coupled with TNF receptor associated factor (TNF receptor associated factor, TRAF) to activate the NF-κB pathway. Finally, induce the expression of anti-apoptotic genes: Bcl-2, Bcl-xL, and reduce the apoptosis of mature ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/08C12N15/70C12N15/66C07K19/00
Inventor 孙剑冯建男沈倍奋赵亚璁白乌仁图雅冀丽军郝霞飞
Owner TIANJIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap